Connection
Dexiang Gao to Interleukin-2
This is a "connection" page, showing publications Dexiang Gao has written about Interleukin-2.
|
|
Connection Strength |
|
|
|
|
|
0.236 |
|
|
|
-
Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5.
Score: 0.113
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
Score: 0.052
-
Iguchi N, Hecht SL, Gao D, Wilcox DT, Malykhina AP, Cost NG. Sexual dimorphic impacts of systemic vincristine on lower urinary tract function. Sci Rep. 2022 03 24; 12(1):5113.
Score: 0.048
-
Kounalakis N, Gao D, Gonzalez R, Becker M, Lewis K, Poust J, Pearlman N, Robinson W, McCarter M. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|